Portfolio

Epirium Bio

Mitochondrial Biogenesis

Epirium Bio is developing a new class of therapeutics that stimulates muscle growth and strength as well as benefiting biogenesis in other tissues. The Company has clinical data in several degenerative muscle disease indications including Becker’s Muscular Dystrophy. Founded by George Schreiner MD PhD and Sundeep Dugar PhD.

Series A Investor and Board member

Forty Seven

Immuno-Oncology

Forty Seven developed an antibody against CD47, a “Don’t Eat Me” signal that regulates immune activity against many cancers. Founded by Irv Weissman MD (Director of the Stanford Stem Cell Institute) and Ravi Majeti MD PhD, Chair of Hematology at Stanford. The Company went public in 2018 and was acquired by Gilead in 2019 for $4.9 billion.

Series A Investor and Lead Director

Kriya Therapeutics

Gene Therapy

Kriya Therapeutics is a gene therapy company focused on major medical indications including Diabetes and Ophthalmologic diseases and with cutting edge manufacturing capabilities. Founded by Shankar Ramaswamy MD, Roger Jeffs PhD, and Fraser Wright PhD of Stanford.

Series A Investor

Medikine Therapeutics

Cytokine Activating Cancer Drugs

Medikine is developing peptide-based cytokine activating drugs for use in cancer treatement. The Company is led by CEO Ron Barrett, PhD, past head of Xenoport.

Series Seed Investor

Nutcracker Therapeutics

RNA Therapeutics

Nutcracker Therapeutics is disrupting the manufacturing process for RNA Therapeutics by developing a “GMP factory in a box” to enable agile RNA drug development. Founded by Igor Khandros, past founder of Berkeley Lights.

Series A Investor

Procyrion

Congestive Heart Failure

Procyrion is a developing a medical device to treat Congestive Heart Failure and associated renal disease using an innovative implantable intravascular pump. Clinical studies begin in late 2020. Led by CEO Eric Fain, MD formerly of Abbott and St Jude Medical.

Series D Investor and Board member